Abstract 1155P
Background
Lung cancer centers are responsible for coordinating the care of lung cancer patients in a region and to diagnose and treat them according to the latest evidence-based knowledge. In the tumor board an individual treatment plan is discussed and treatment recommendations are given. Therefore, we investigate: 1.) how are the recommendations from tumor boards being adhered to; 2.) which factors determine the adherence of tumor board recommendations and 3.) what is the relationship between the adherence of tumor board recommendations and patient outcomes in terms of OS?
Methods
Data from 1784 newly-diagnosed patients with lung cancer discussed in tumor boards in one certified lung cancer center in Northern Germany between 2014 and 2018 were documented and evaluated according to the adherence to tumor board recommendations. An analysis of 644 cases analyzed will be presented. Data was analyzed descriptively.
Results
Median age of the 644 patients was 66 years (26-91 yrs) and 66% (n=428/644) of them were male. Most of the patients had an ECOG of 0 or 1 (85%; n=548/644) and 87% of them were current or ex heavy smoker (n=561/644). In 85% (n=545/644) of patients, the treatment recommendations from the multidisciplinary tumor boards were completely adhered to. There were different reasons for non-adherence, e.g. patient’s wish, patient characteristics and death before starting therapy. The median OS for the 644 patients was 15 months. Patients with a complete adherence to the multidisciplinary tumor board recommendation had an OS of 17 months (n=545) compared to 5 months (n=61) for patients with a partial adherence compared to 4 months (n=38) for patients with a non-adherent treatment (p<0.000).
Conclusions
Preliminary results give a hint to the fact that patients with an adherent treatment after first diagnosis had a longer overall survival than patients with another therapy. More cases will be presented at the meeting using a multivariate analysis which includes patient characteristics and healthcare organizations that took over further treatment as predictors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Roeper: Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, Roche, AstraZeneca; Financial Interests, Personal, Writing Engagements: AstraZeneca. F. Griesinger: Financial Interests, Personal, Invited Speaker, Advisory Board and Research Grant: Boehringer Ingelheim, AstraZeneca, BMS, Celgene, MSD, Lilly, Novartis, Pfizer, Roche, Takeda; Financial Interests, Personal, Invited Speaker, Advisory Board: Siemens, Amgen, Ariad, AbbVie, Tesaro/GSK. All other authors have declared no conflicts of interest.